ABSTRACT
In 2015, Bangladesh introduced the ten-valent pneumococcal conjugate vaccine (PCV10). This study evaluates the impact of PCV10 on pneumococcal otitis media (OM), a prevalent middle ear infection amongst children in low-and-middle income countries, including Bangladesh. We analyzed ear swabs from OM cases with otorrhea collected at the largest pediatric hospital in Dhaka, Bangladesh from April 2014 to March 2019. The study involved identifying pathogens and conducting pneumococcal serotyping using the Quellung reaction.
Four years post PCV10 introduction, the rate of detection of pneumococcus among otorrhea cases decreased from 18.4% (164/892) in 2014-15 to 15.6% (581/3735) in 2018-19, reflecting a 15.4% reduction. Notably, vaccine serotypes (VTs) demonstrated a significant decline throughout the post-PCV years, with a 44.1% reduction compared to the pre-PCV period. Specific VTs like 14, 6B and 19F exhibited significant reductions of 60.2%, 57.5% and 42.9% respectively. Conversely, non-vaccine serotypes (NVTs) showed non-significant increase of 8.6%; specifically serotype 35B showed a 70.1% increase. Administration of two or three doses of PCV10 provided 84.4% protection against OM cases caused by serotypes covered by PCV10.
This is the first report from South Asia assessing PCV’s impact on pneumococcal OM. It demonstrates a 15.4% reduction in pneumococcal isolation over four years and over 80% efficacy of PCV10 in preventing vaccine type pneumococcal OM cases. While some vaccine serotypes decreased significantly, the impact of PCV10 on overall pneumococcal OM cases was dampened by increasing isolation of non-vaccine serotypes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Pfizer Inc (Grant number: WI209075). The funding organization had no role in the design, implementation, data analysis, manuscript writing or decision to publish this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This surveillance protocol was approved by the Institutional Review Board of Bangladesh Institute of Child Health at the Bangladesh Shishu Hospital and Institute, Dhaka, Bangladesh (formerly known as Dhaka Shishu Hospital).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
We realized S. pneumoniae was written in the legend as S. influenzae in Figure 2.
Data Availability
All data produced in the present work are contained in the manuscript.
